Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma

Abstract

Gliomas are the most common form of central nervous system tumor. The most prevalent form, glioblastoma multiforme, is also the most deadly with mean survival times that are less than 15 months. Therapies are severely limited by the ability of these tumors to develop resistance to both radiation and chemotherapy. Thus, new tools are needed to identify and monitor chemoresistance before and after the initiation of therapy and to maximize the initial treatment plan by identifying patterns of chemoresistance prior to the start of therapy. Here we show how magnetic resonance imaging, particularly sodium imaging, metabolomics, and genomics have all emerged as potential approaches toward the identification of biomarkers of chemoresistance. This work also illustrates how use of these tools together represents a particularly promising approach to understanding mechanisms of chemoresistance and the development individualized treatment strategies for patients.

Keywords

Sodium MRI / diffusion / genes / resistance / glycolysis / warburg effect

References

[1] Hanif F,Perveen K,Simjee SU.Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment..Asian Pac J Cancer Prev2017;18:3-9 PMCID:PMC5563115

[2] Hatoum A,Zakieh O.The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix..Cancer Manag Res2019;11:1843-55 PMCID:PMC6395056

[3] Ohgaki H.Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas..J Neuropathol Exp Neurol2005;64:479-89

[4] Hashmi FA,Shamim MS.Biological characteristics and outcomes of Gliosarcoma..J Pak Med Assoc2018;68:1273-75

[5] Song A,Werner-Wasik M,Glass J.Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas..Radiother Oncol2019;132:135-41

[6] Cloughesy TF,Vogelbaum MA,Elder JB.Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC..Neuro Oncol2018;20:1383-92 PMCID:PMC6120351

[7] Migliorini D,Allard M,Marinari E.Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients..Neuro Oncol2019;Feb12

[8] Laub CK,Doherty L.Approved treatments for patients with recurrent high-grade gliomas..Semin Oncol Nurs2018;34:486-93

[9] Serventi J.Surgery and evidence-based treatments in patients with newly diagnosed high-grade glioma..Semin Oncol Nurs2018;34:443-53

[10] Thon N,Kreth FW.The surgical perspective in precision treatment of diffuse gliomas..Onco Targets Ther2019;12:1497-1508 PMCID:PMC6390867

[11] Scott JG,Elson P,Vogelbaum MA.Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases..Neuro Oncol2011;13:428-36 PMCID:PMC3064699

[12] Khan KA,Ali N.Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma..J Coll Physicians Surg Pak2014;24:935-9

[13] Donovan LE.Chemotherapy treatment and trials in low-grade gliomas..Neurosurg Clin N Am2019;30:103-9

[14] Lukas RV,Ladomersky E,Sonabend AM.Newly Diagnosed Glioblastoma: A Review on Clinical Management..Oncology2019;33:91-100

[15] Liu R,Tao B,Yang Z.Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance..Nat Commun2019;10:991 PMCID:PMC6397164

[16] Daniel P,Chaddad A,Jean-Claude B.Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities..Front Oncol2019;9:41 PMCID:PMC6369148

[17] Raguz S.Resistance to chemotherapy: new treatments novel insights into an old problem..Brit J Cancer2008;99:387-91 PMCID:PMC2527800

[18] Goldi JH.Drug resistance in cancer: A perspective..Cancer and Metastasis Rev20:163-8

[19] Ahmed R,Hwang M,Mountz JM.Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods..Cancer Manag Res2014;6:149-70 PMCID:PMC3969256

[20] Neal A,Stein JM,Desmond P.Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging..Neuroimage Clin2019;22:101694 PMCID:PMC6396013

[21] Shen X,Larkin SJ,Plaha P.A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy..Metabolites2019;9:35 PMCID:PMC6409728

[22] Hilario A,Sepulveda JM,Perez-Nuñez A.Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival..Neurocirugia (Astur)2019;30:11-8

[23] Fahlström M,Nyholm T.Perfusion magnetic resonance imaging changes in normal appearing brain tissue after radiotherapy in glioblastoma patients may confound longitudinal evaluation of treatment response..Radiol Oncol2018;52:143-51 PMCID:PMC6043875

[24] Hamstra DA,Moffat BA,Meyer CR.Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma..Proc Natl Acad Sci U S A2005;102:16759-64 PMCID:PMC1276616

[25] Hamstra DA,Meyer CR,Sundgren PC.Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival..J Clin Oncol2008;26:3387-94 PMCID:PMC3266717

[26] Pope WB,Huo J,Brown MS.Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment..Radiology2009;252:182-9

[27] Nowosielski M,Goebel G,Tinkhauser G.ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma..Neuroradiology2011;53:291-302 PMCID:PMC3063200

[28] Ross BD,Lawrence TS,Gebarski SS.Evaluation of cancer therapy using diffusion magnetic resonance imaging..Mol Cancer Ther2003;2:581-7

[29] Chenevert TL,Moffat BA,Mukherji SK.Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy..Mol Imaging2002;1:336-43

[30] Schepkin VD,Chenevert TL,Sharma S.Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma..Magn Reson Med2005;53:85-92 PMCID:PMC3121241

[31] Laymon CM,Lee VK,Wiener EC.Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis..Magn Reson Imaging2012;30:1268-78 PMCID:PMC3823553

[32] Thulborn KR,Adams H,Zhou J.Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging..Magn Reson Med1999;41:351-9

[33] Schepkin VD,Kitchen JA,Gor’kov PL.In vivo chlorine and sodium MRI of rat brain at 21.1 T..MAGMA2014;27:63-70 PMCID:PMC5523823

[34] Schepkin VD,Kuszpit K,Johnson TD.Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance..NMR Biomed2006;19:1035-42 PMCID:PMC3140794

[35] Schepkin VD,Kuszpit K,Meyer CR.Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors..Magn Reson Imaging2006;24:273-8 PMCID:PMC3127446

[36] Bartha R,Watling CJ.Low-grade glioma: correlation of short echo time 1H-MR spectroscopy with 23Na MR imaging..AJNR Am J Neuroradiol2008;29:464-70

[37] Ouwerkerk R,Gillen JS,Bottomley PA.Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging..Radiology2003;227:529-37

[38] Nagel AM,Hartmann C,Neumann JO.The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors..Invest Radiol2011;46:539-47

[39] Nunes Neto LP,Sood TP,Kondziolka D.Quantitative sodium imaging and gliomas: a feasibility study..Neuroradiology2018;60:795-802 PMCID:PMC6070137

[40] Lee KC,Hoff BA,Sharma S.Dynamic imaging of emerging resistance during cancer therapy..Cancer Res2006;66:4687-92

[41] Schepkin VD.Sodium MRI of glioma in animal models at ultrahigh magnetic fields..NMR Biomed.2015;29:175-86

[42] Schepkin VD,Morgan T,Ozambela M Jr.In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T..Magn Reson Med2012;67:1159-66 PMCID:PMC3193856

[43] Budinger TF,Frydman L,Mareci TH.Toward 20 T magnetic resonance for human brain studies: opportunities for discovery and neuroscience rationale..MAGMA2016;29:617-39 PMCID:PMC5538368

[44] Warburg O.On respiratory impairment in cancer cells..Sci1956;124:269-70

[45] DeBerardinis RJ,Ditsworth D.Brick by brick: metabolism and tumor cell growth..Curr Opin Gen Devel2008;18:54-61 PMCID:PMC2476215

[46] Koukourakis M,Pouliliou S,Papadopoulou M.Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide..Biochem Biophys Res Commun2017;491:932-8

[47] Venneti S.Metabolic teprogramming in brain tumors..Annu Rev Pathol2017;12:515-45

[48] Libby CJ,Scott SE,Hjelmeland AB.The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells..Biochim Biophys Acta Rev Cancer2018;1869:175-88

[49] Cairns RA,Mak TW.Regulation of cancer cell metabolism..Nat Rev Cancer2011;11:85-95

[50] Fogg VC,MacKeigan JP.Mitochondria in cancer: at the crossroads of life and death..Chin. J. Cancer2011;30:526-539 PMCID:PMC3336361

[51] Kroemer G.Tumor cell metabolism: Cancer’s Achilles’ heel..Cancer Cell2008;13:472-82

[52] Bensinger SJ.New aspects of the Warburg effect in cancer cell biology. Semin..2012;23:352-361

[53] Yuen CA,Guda MR,Velpula KK.Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept..CNS Oncol2016;5:101-8 PMCID:PMC6047435

[54] Marin-Valencia I,Mashimo T,Baek H.Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo..Cell Metab2012;15:827-37 PMCID:PMC3372870

[55] Mischel PS.HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth..Cell Metab2012;15:789-90 PMCID:PMC3376384

[56] Oliva C,Diers A,Sarkaria J.Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain..J Biol Chem2010;285:39759-67 PMCID:PMC3000957

[57] Oliva C,Gillespie GY.Acquisition of chemoresistance in gliomas Is associated with I\increased mitochondrial coupling and decreased ROS production..PloS One2011;6:e24665 PMCID:PMC3170372

[58] Le Calvé B,Le Mercier M,Lonez C.Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression..Neoplasia2010;12:727-39 PMCID:PMC2933693

[59] St-Coeur PD,Cuperlovic-Culf M,Morin P Jr.Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics..J Neurooncol2015;125:91-102

[60] Shen H,Dilda PJ,Chung SA.Dual-targeting of aberrant glucose metabolism in glioblastoma..J Exp Clin Cancer Res2015;34:14 PMCID:PMC4324653

[61] Team RDCR: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria2008;

[62] Katz J,Wals PA.Studies of glycogen synthesis and the Krebs cycle by mass isotopomer analysis with [U-¹³C] glucose in rats..J Biol Chem1989;264:12994-13004

[63] Katz J,Lee WNP.Isotopomer studies of gluconeogenesis and the krebs cycle with 13C-labeled lactate..J Biol Chem1993;268:25509-21

[64] Fernandez CA.Modeling of liver citric acid cycle and gluconeogenesis based on ¹³C mass isotopomer distribution analysis of intermediates..J Biol Chem1995;270:10037-42

[65] Michelakis ED,Dromparis P,Haromy A.Metabolic modulation of glioblastoma with dichloroacetate..Sci Transl Med2010;2:31-4

[66] Kastl L,Schofield A.Altered DNA methylation is associated with docetaxol resistance in human breast cancer cells..Int J Oncol2010;36:1235-41

[67] Candelaria M,Taja-Chayeb L,Trejo-Becerril C.DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells..PloS One2012;7:e29181 PMCID:PMC3299634

[68] Hervouet E,Vallette FM.DNA methylation and apoptosis resistance in cancer cells..Cells2013;2:545-73 PMCID:PMC3972670

[69] Bruzzone MG,Cuccarini V,Valletta L.Genetic signature of adult gliomas and correlation with MRI features..Expert Rev Mol Diagn2009;9:709-20

[70] Riemenschneider MJ,Wesseling P.Molecular diagnostics of gliomas: state of the art..Acta Neuropathol2010;120:567-84 PMCID:PMC2955236

[71] Bartesaghi S,Galavotti S,Betts J.Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells..Proc Natl Acad Sci U S A2015;112:1059-64 PMCID:PMC4313844

[72] Stepanenko AA,Korets KV,Baklaushev VP.Temozolomide promotes genomic and phenotypic changes in glioblastoma cells..Cancer Cell Int2016;16:36 PMCID:PMC4858898

[73] Immanuel SRC,Parmar DS,Panchagnula V.Integrative analysis of rewired central metabolism in temozolomide resistant cells..Biochem Biophys Res Commun2018;495:2010-6

[74] Suwala AK,Rios DH,Uhlmann C.Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro..Oncotarget2018;9:22703-16

[75] Calvert AE,Wu Y,Kouri FM.Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation..Cell Rep2017;19:1858-73 PMCID:PMC5564207

[76] Beig N,Prasanna P,Gupta A.Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma..Sci Rep2018;8:7 PMCID:PMC5758516

[77] Agrawal R,Jha P,Sarkar C.Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing..BMC Genomics2014;15:686 PMCID:PMC4148931

[78] Giovannetti E,Smit J,Peters GJ.Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice..Crit Rev Oncol Hematol2012;81:103-22

[79] Tabet A,Parkins CC,Watts C.Designing next-generation local drug delivery vehicles for glioblastoma adjuvant chemotherapy: lessons from the clinic..Adv Healthc Mater2019;8:e1801391

[80] Ius T,Isola M,Pauletto G.Combining clinical and molecular data to predict the benefits of carmustine wafers in newly diagnosed high-grade gliomas..Curr Treat Options Neurol2018;20:3

[81] Sippl C,Bohr L,List M.miRNA-181d expression significantly affects treatment responses to carmustine wafer implantation..Neurosurgery2019;85:147-55

[82] Zhang L,Zhang W,Huang Q.Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance..J Neurochem2017;142:574-88

[83] Meco D,Melotti L,Riccardi R.Ectopic nerve growth factor prevents proliferation in glioma cells by senescence induction..J Cell Physiol2019;234:6820-30

[84] Persaud SD,Ishigami-Yuasa M,Kagechika H.All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation..Sci Rep2016;6:27678 PMCID:PMC4776112

[85] Ikemori RY,Furuzawa KM,Osinaga E.Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival..PLoS One2014;9:e111592 PMCID:PMC4219723

[86] Khalil AA.Biomarker discovery: a proteomic approach for brain cancer profiling..Cancer Sci2007;98:201-13